We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Gilead’s Antiviral Remdesivir Prevents Disease Progression in Monkeys with COVID-19

By HospiMedica International staff writers
Posted on 21 Apr 2020
Print article
Image: Gilead’s Antiviral Remdesivir Prevents Disease Progression in Monkeys with COVID-19  (Photo courtesy of Gilead Sciences)
Image: Gilead’s Antiviral Remdesivir Prevents Disease Progression in Monkeys with COVID-19 (Photo courtesy of Gilead Sciences)
A study by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases {(NIAID) Rockville, MD, USA} has found that early treatment with Gilead Sciences’ (Foster City, CA, USA) remdesivir significantly reduced clinical disease and damage to the lungs of rhesus macaques infected with SARS-CoV-2. The study was designed to follow dosing and treatment procedures used for hospitalized COVID-19 patients being administered the experimental antiviral drug in a large, multi-center, clinical trial

The study involved two groups of six rhesus macaques, with one group receiving remdesivir and the other animals being served as an untreated comparison group. The scientists infected both the groups with SARS-CoV-2 and administered an intravenous dose of remdesivir to the treatment group after 12 hours, followed by a daily intravenous booster dose for the next six days. The scientists timed the initial treatment to occur shortly before the virus reached its highest level in the animals’ lungs.

The scientists examined all animals 12 hours after the initial treatment and found the six treated animals to be in significantly better health than the untreated group, with the trend continuing over the course of the seven-day study. One of the six treated animals exhibited mild breathing difficulty, whereas all the six untreated animals showed rapid and difficult breathing. The amount of virus found in the lungs of the animals in the treatment group was significantly than those in the untreated group, and SARS-CoV-2 caused less damage to the lungs of the treated animals than the untreated animals.

The scientists believe that the data supports initiating remdesivir treatment in COVID-19 patients as early as possible to achieve maximum treatment effect, although they have noted that while remdesivir helped prevent pneumonia, it did not reduce virus shedding by the animals.

Related Links:
Gilead Sciences
National Institute of Allergy and Infectious Diseases


Gold Supplier
Creatinine Meter
StatSensor Xpress Creatinine Meter
New
Abdominal Stent Graft Platform
Ovation iX
New
Chair Scale
seca 954
New
Multi-Parameter Patient Monitor
S80

Print article
FIME - Informa

Channels

AI

view channel
Image: The AI tool can also tackle dangerous inequalities in heart attack diagnosis (Photo courtesy of Freepik)

AI Algorithm Integrates Cardiac Troponin Test Results with Clinical Data to Quickly Rule out Heart Attacks in Patients

The accepted standard for diagnosing myocardial infarction, or heart attack, involves assessing the blood for troponin levels. However, this approach applies the same benchmark for all patients, failing... Read more

Critical Care

view channel
Image: New technology gives patients the power to heal chronic wounds using their own blood (Photo courtesy of RedDress)

POC Solution Creates In Vitro Blood Clots from Patient’s Own Whole Blood in Real-Time to Treat Post-Surgical Wounds

Blood clots are a natural mechanism of the body's healing process. However, for chronic wounds resulting from diabetes and other conditions, blood is unable to reach these areas, hampering the initiation... Read more

Surgical Techniques

view channel
Image: The deployable electrodes are ideal for minimally invasive craniosurgery (Photo courtesy of EPFL)

Soft Robotic Electrode Offers Minimally Invasive Solution for Craniosurgery

Minimally invasive medical procedures offer numerous benefits to patients, including decreased tissue damage and shorter recovery periods. However, creating equipment that can pass through a small opening... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: IntelliSep is the first FDA-cleared diagnostic tool to assess cellular host response to aid in identifying ED patients with sepsis (Photo courtesy of Cytovale)

Rapid Microfluidic Test Demonstrates Efficacy as Diagnostic Aid to Improve Sepsis Triage in ED

Sepsis is the primary cause of mortality worldwide, accounting for over 350,000 fatalities annually in the United States alone, a figure that surpasses deaths from opioid overdoses, prostate cancer, and... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.